EDUCATIONAL CANCER CONVENTION LUGANO

WHAT’S NEW AND WHAT’S TRUE IN GENITO-URINARY ONCOLOGY?

12-14 May 2011
Lugano, Switzerland

Chair: D. Berthold, CH and B. Tombal, BE

ECCLU 2011 is held under the auspices of the European School of Urology
On behalf of ESO and of the Scientific Committee, we have the pleasure of inviting you to attend the Educational Cancer Convention Lugano.

The 2011 edition will be devoted to genito-urinary oncology with a programme developed with special attention the multidisciplinary care of patients with prostate, bladder, renal and testicular cancer. The program should be equally interesting for urologists, radiation and medical oncologists as well as clinicians in training in those specialities. The programme includes state of the art lectures, controversies and gives ample time for discussion of abstracts and clinical cases provided by the participants.

We look forward to welcome you to ECCLU 2011 and to your active participation.

*Dominik Berthold and Bertrand Tombal, Course Chairmen*
Acknowledgments

ESO is grateful to the City of Lugano for their interest and continuous support in the organisation of ECCLU, to the European Society for Medical Oncology for their co-operation and support of travel grants and to the European School of Urology for their collaboration in the programme and assistance in the promotion of the event.

Official language
The official language of the Convention will be English. No translation will be provided.

Abstract book
The abstract book will be published as a supplement to the Critical Reviews in Oncology/Hematology and will contain abstracts of the invited lectures and those submitted by the participants that have been accepted for oral or poster presentation.

Important deadlines

- By 15 February 2011: Abstract submission
- By 21 February 2011: Early registration
- By 26 April 2011: Late registration
Faculty

**J. J. Battermann**, University Medical Centre Utrecht, Dept. of Radiotherapy, Utrecht, NL

**J. Bellmunt**, Hospital del Mar, Medical Oncology Service, Barcelona, ES

**D. Berthold**, University Hospital Canton Vaud, Pluridisciplinary Centre for Oncology, Lausanne, CH

**A. Bex**, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hos, Department of Urology, Amsterdam, NL

**M. Bolla**, University Hospital of Grenoble - La Tronche, Department of Radiotherapy, Grenoble, FR

**C. Bosetti**, Mario Negri Institute for Pharmacological Research, Department of Epidemiology, Milan, IT

**N. Clarke**, Christie Hospital and Salford Royal Hospitals NHS Trusts, Department of Urological Oncology, Manchester, UK

**A. Costa**, European School of Oncology, Scientific Director, Bellinzona CH and Milan, IT

**Z. Culig**, Innsbruck Medical University, Department of Urology, Innsbruck, AT

**J.S. de Bono**, The Royal Marsden Hospital, Institute of Cancer Research, Sutton, UK

**M. De Santis**, Kaiser Franz Josef Hospital - SMZ Süd, Center for Oncology and Hematology, Vienna, AT

**V. Ficarra**, University of Padua, Urologic Clinic, Department of Oncologic and Surgical Sciences, Padova, IT

**K. Fizazi**, Institut Gustave Roussy, Department of Cancer Medicine, Villejuif, FR

**V. Griesser**, Europa Uomo Switzerland, Châtel-St-Denis, CH
Programme

THURSDAY, 12 MAY

10:45  Welcome
       D. Berthold, CH – A. Costa, IT/CH
       Representative of the Town of Lugano

11:00  Epidemiology in Europe
       C. Bosetti, IT

11:15  Localised invasive bladder cancer
       Chair: A. Bex, NL
       - Neo-adjuvant chemotherapy
         J. Bellmunt, ES
       - Surgery
         G. Thalmann, CH
       - Radiotherapy
         N. James, UK

12:30  Palliative chemotherapy: First-line, second-line, platinum-unfit
       M. De Santis, AT

13:00  Lunch and poster session

14:00  Oral abstract presentations / Case reports
       Chair: I. Tannock, CA

14:45  Mechanisms of action in modern RCC treatment
       (Lecture sponsored by Novartis Oncology)
       Ch. Rothermundt, CH

15:15  Coffee break

15:45  Kidney cancer
       Chair: G. Thalmann, CH
       - First and further lines in mRCC
         B.I. Rini, US
       - Adjuvant and neo-adjuvant treatment
         A. Bex, NL
       - Non-clear cell histology
         J. Bellmunt, ES
       - Surgery (including nephron-sparing surgery)
         H. Van Poppel, BE
18:15  **Keynote lecture: New developments in the systemic treatment of advanced prostate cancer**  
I. Tannock, CA  
*(the lecture will be webcast as part of the e-grandround programme [www.e-eso.net](http://www.e-eso.net))*

19:00  **Welcome cocktail**

**FRIDAY, 13 MAY**

8:30  **Prostate cancer: From biology to live expectancy**  
*Chair:* Ch. Parker, UK  
- **Biology**  
  Z. Culig, AT  
- **Screening and active surveillance**  
  F.C. Hamdy, UK  
- **Predicting life expectancy**  
  C. Terret, FR

10:30  **Coffee break**

11:00  **Prostate cancer: All the truth about local treatment options T1-T2**  
*Chair:* F.C. Hamdy, UK  
- **Radiotherapy**  
  A. Widmark, SE  
- **Surgery**  
  V. Ficarra, IT  
- **Brachytherapy**  
  J.J. Battermann, NL  
- **High-intensity focused ultrasound and cryotherapy**  
  F.J. Murat, FR

12:20  **Oral abstract presentations / Case reports**  
*Chair:* D. Berthold, CH

13:00  **Lunch and poster session**
14:00  **Controversy: Locally advanced prostate cancer**  
*Moderator:* B. Tombal, BE

- **Pro surgery**  
  A. Heidenreich, DE

- **Pro radiation**  
  Ch. Parker, UK

- **Discussion and conclusion**  
  B. Tombal, BE

15:00  **Locally advanced prostate cancer: Multimodality treatment and new drugs combined with radiotherapy**  
S. Supiot, FR

15:30  **Coffee break**

16:00  **Prostate cancer: Locally advanced disease and patient advocacy**  
*Chair:* D. Berthold, CH

- **Europa Uomo: The patients’ voice**  
  V. Griesser, CH

- **Adjuvant versus salvage radiation**  
  M. Bolla, FR

- **Integrating systemic therapy into high-risk disease**  
  K. Fizazi, FR

17:00  **Prostate cancer: Managing pelvic lymph nodes and related toxicity**  
*Chair:* A. Heidenreich, DE

- **Surgical perspective**  
  H. Van Poppel, BE

- **Radiation perspective**  
  Th. Wiegel, DE

**SATURDAY, 14 MAY**

9:00  **Prostate cancer drug development**  
J.S. de Bono, UK

10:00  **SIOG guidelines for the management of prostate cancer in senior adults**  
(Lecture sponsored by Sanofi-Aventis)  
C. Terret, FR

10:30  **Coffee break**
11:00  Side-effects of anti-androgen therapy  
B. Tombal, BE

11:30  Bone targeted agents  
N. Clarke, UK

12:00  Testicular cancer  
N. Clarke, UK
  - Options in stage I testicular cancer  
    A. Horwich, UK
  - Treatment of advanced testicular cancer  
    K. Fizazi, FR
  - Role of surgery in the management of testis cancer  
    A. Heidenreich, DE

13:30  Closing remarks  
D. Berthold, CH

13:40  Distribution of CME certificates and departures

Organising Secretariat

European School of Oncology
ESO Bellinzona Office
Ospedale Regionale
6500 Bellinzona - Switzerland
Tel: +41 91 811 8050 - Fax: +41 91 811 8051
Website: www.eso.net

Programme and organisation
Chatrina Melcher  cmelcher@eso.net

Abstracts and programme
Dolores Knupfer  dknupfer@eso.net

Registration
Registration  lrichetti@eso.net
Venue

Palazzo dei Congressi, Lugano, Switzerland

Lugano is reachable by plane via Zurich (45-minute flight or 2.5-hour train) or from Milano Malpensa airport (2-hour drive, shuttle service).

How to reach Lugano:

Airplane

Lugano-Agno Airport (LUG) is located at 6 km from the town and it is the ideal point of arrival. A shuttle service to/from the centre and hotels is available. Please visit www.shuttle-bus.com for further information.

Train

Fast and easy connections by train are available to Zurich (3 hours) or to Milan Central Station (not airport!).

Milano Malpensa

The transfer from the Milano Malpensa airport to Lugano takes approximately 1 hour and 15 minutes. Please note that booking is required. More information on schedule, duration, cost and booking form for the transfer are available at www.malpensaexpress.ch or www.starstation.ch
Registration

Registration grants participation in all sessions, a copy of the programme and of the abstract book, coffee breaks and lunches as indicated in the programme.

<table>
<thead>
<tr>
<th></th>
<th>Early (by 21 February)</th>
<th>Late (by 26 April)</th>
<th>Onsite (from 27 April)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Registration fee</strong></td>
<td>EUR 250</td>
<td>EUR 350</td>
<td>EUR 500</td>
</tr>
<tr>
<td><strong>ESMO Members</strong></td>
<td>EUR 200</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Club ESO Members</strong></td>
<td>EUR 200</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cancellation of registration or replacement
Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee less handling charges of EUR 100 will be refunded after the event, provided that the cancellation is received by ESO before 21 February 2011. Replacements will be possible till 21 February 2011.

Confirmation of registration
Registration will be confirmed preferably by e-mail, or by fax or by mail.

Travel grants
A limited number of travel grants are assigned on a competitive basis from among participants from middle-low income countries who have had an abstract accepted for oral or for poster presentation.

The curriculum vitae should be submitted at the same time as the abstract (deadline: 15 February) indicating the amount requested to cover economy fare. Successful applicants will be granted registration, accommodation for 2 nights and refund of actual travel costs (flight only) on site at the end of the Convention.
General information

**Badge**
The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.

**Insurance**
The organisers bear no responsibility for untoward events in relation with the participation in the Convention. Participants are advised to take out their own personal and travel insurance coverage.

**Continuing Medical Education and certificates**
All participants will be issued a certificate of attendance at the close of the Convention.
Application for CME recognition will be submitted to ESMO for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS).
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising secretariat.
Hotel accommodation

Palazzo dei Congressi
Attn. Mrs. Gabriela Zuber
Piazza Indipendenza 4
6900 Lugano, Switzerland
Tel: +41 91 911 0404 - Fax: +41 91 921 1460
Email: hotel@lugano-conventions.com

Palazzo dei Congressi is the official accommodation agent for ECCLU 2011 and has secured hotel rooms in all categories. Requests for bookings will be received by the Palazzo dei Congressi who will assign a room. The participant should then refer to the hotel directly regarding guarantee, payment procedure and conditions for cancellation. Requests are processed on a first-come/first-served basis whilst should the desired hotel no longer be available, a similar hotel will be proposed by the Palazzo dei Congressi.

Hotel rates are indicated in Swiss Francs (CHF), inclusive of VAT and breakfast. The tourist tax is not included. Please refer to the Hotel Accommodation Form for detailed list of hotels and rates.

Sharing Progress in Cancer Care

ECCLU is part of the Sharing Progress in Cancer Care programme whose sustaining members are:

Platinum members: Amgen and Eisai
Gold members: Eli Lilly, GlaxoSmithKline Oncology and Merck Serono
Silver members: Genomic Health, Novartis Oncology and Sanofi-Aventis
Abstract submission

Deadline for submission 15 February 2011
Submit online at www.eso.net

Participants are invited to submit an abstract on basic research, clinical study or a clinical case in genito-urinary oncology, in one of the following categories:

- Bladder cancer
- Kidney cancer
- Prostate cancer
- Testicular cancer

Abstracts on basic research will be considered for poster presentation only.
Abstracts on clinical cases or clinical studies will be considered for oral presentation or poster presentation.

Participants submitting abstracts on a clinical case are encouraged to describe frequent disorders, where a clinical-therapeutic decision making is controversial.
The oral presentation of clinical cases or clinical studies will be scheduled with a 5-minute presentation (maximum of 5 slides) followed by a 5-minute discussion.

Accepted abstracts will be published in the ECCLU 2011 Abstract Book, supplement to the Critical Reviews in Oncology/Hematology.
Instructions:

• The abstract should be limited to 2000 characters, including the title.
• The title should be in lower case letters.
• Each author should be listed with First Name, followed by Family Name.
• The first author should be underlined (first author = corresponding author and presenter).
• List affiliations after the authors' list.
• The full address with e-mail address, phone and fax numbers of the first author (+ corresponding author and presenter) must be provided. The first author will receive an acknowledgement of receipt and all subsequent communication by e-mail.
• For abstracts accepted for presentation, the first author will be the presenting author and is requested to register and participate in the Convention.
• It is the responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made.

The acknowledgement of receipt of the abstract will immediately follow the submission. The outcome will be notified by the end of February to the first author who will be required to register to the Convention.
European School of Oncology
ESO Bellinzona Office
Ospedale Regionale
6500 Bellinzona, Switzerland
Tel: +41 91 811 8050
Fax: +41 91 811 8051

Website: www.eso.net